{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:28:43Z","timestamp":1791808123555,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS064096"],"award-info":[{"award-number":["U01NS064096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41434-020-00190-1","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T15:03:47Z","timestamp":1599145427000},"page":"142-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease"],"prefix":"10.1038","volume":"28","author":[{"given":"Victoria J.","family":"McCurdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aime K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Gray-Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley N.","family":"Randle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy R.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sena-Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8407","authenticated-orcid":false,"given":"Douglas R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"190_CR1","unstructured":"Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K. The GM2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. Vol. 3, chapter 153."},{"key":"190_CR2","first-page":"900","volume":"35","author":"E Conzelmann","year":"1983","unstructured":"Conzelmann E, Kytzia H, Navon R, Sandhoff K. Ganglioside GM2 N-acetyl-beta-D-galactosaminidase activity in cultured fibroblasts of late-infantile and adult GM2 gangliosidosis patients and of healthy probands with low hexosaminidase level. Am J Hum Genet. 1983;35:900\u201314.","journal-title":"Am J Hum Genet."},{"key":"190_CR3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1705155","volume":"36","author":"J Jacobs","year":"2005","unstructured":"Jacobs J, Willemsen M, Groot-Loonen J, Wevers R, Hoogerbrugge P. Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease. Bone Marrow Transplant. 2005;36:925\u20136.","journal-title":"Bone Marrow Transplant."},{"key":"190_CR4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/01.wnl.0000194225.78917.de","volume":"66","author":"B Bembi","year":"2006","unstructured":"Bembi B, Marchetti F, Guerci V, Ciana G, Addobbati R, Grasso D, et al. Substrate reduction therapy in the infantile form of Tay-Sachs disease. Neurology. 2006;66:278\u201380.","journal-title":"Neurology."},{"key":"190_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/GIM.0b013e3181a1b5c5","volume":"11","author":"BE Shapiro","year":"2009","unstructured":"Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med. 2009;11:425\u201333.","journal-title":"Genet Med."},{"key":"190_CR6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2009.06.005","volume":"98","author":"GH Maegawa","year":"2009","unstructured":"Maegawa GH, Banwell BL, Blaser S, Sorge G, Toplak M, Ackerley C, et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Mol Genet Metab. 2009;98:215\u201324.","journal-title":"Mol Genet Metab."},{"key":"190_CR7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10545-009-1224-7","volume":"32","author":"C Tallaksen","year":"2009","unstructured":"Tallaksen C, Berg J. Miglustat therapy in juvenile Sandhoff disease. J Inherit Metab Dis. 2009;32:289\u201393.","journal-title":"J Inherit Metab Dis."},{"key":"190_CR8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","volume":"102","author":"JTR Clarke","year":"2011","unstructured":"Clarke JTR, Mahuran DJ, Sathe S, Kolodny EH, Rigat BA, Raiman JA, et al. An open-label phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay\u2013Sachs or Sandhoff variants). Mol Genet Metab. 2011;102:6\u201312.","journal-title":"Mol Genet Metab."},{"key":"190_CR9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ymgme.2010.11.163","volume":"102","author":"E Osher","year":"2011","unstructured":"Osher E, Fattal-Valevski A, Sagie L, Urshanski N, Amir-Levi Y, Katzburg S, et al. Pyrimethamine increases \u03b2-hexosaminidase A activity in patients with late onset Tay Sachs. Mol Genet Metab. 2011;102:356\u201363.","journal-title":"Mol Genet Metab."},{"key":"190_CR10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1126\/science.169.3941.141","volume":"169","author":"EF Neufeld","year":"1970","unstructured":"Neufeld EF, Fratantoni JC. Inborn errors of mucopolysaccharide metabolism. Science. 1970;169:141\u20136.","journal-title":"Science."},{"key":"190_CR11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nm0797-771","volume":"3","author":"RM Taylor","year":"1997","unstructured":"Taylor RM, Wolfe JH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat Med. 1997;3:771\u20134.","journal-title":"Nat Med."},{"key":"190_CR12","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1523\/JNEUROSCI.22-15-06437.2002","volume":"22","author":"MA Passini","year":"2002","unstructured":"Passini MA, Lee EB, Heuer GG, Wolfe JH. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci. 2002;22:6437\u201346.","journal-title":"J Neurosci."},{"key":"190_CR13","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","volume":"27","author":"CN Cearley","year":"2007","unstructured":"Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci. 2007;27:9928\u201340.","journal-title":"J Neurosci."},{"key":"190_CR14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/gt.2008.149","volume":"16","author":"M Broekman","year":"2008","unstructured":"Broekman M, Tierney L, Benn C, Chawla P, Cha J, Sena-Esteves M. Mechanisms of distribution of mouse \u03b2-galactosidase in the adult GM1-gangliosidosis brain. Gene Ther. 2008;16:303\u20138.","journal-title":"Gene Ther."},{"key":"190_CR15","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/mt.2012.44","volume":"20","author":"MB Cach\u00f3n-Gonz\u00e1lez","year":"2012","unstructured":"Cach\u00f3n-Gonz\u00e1lez MB, Wang SZ, McNair R, Bradley J, Lunn D, Ziegler R, et al. Gene transfer corrects acute GM2 gangliosidosis\u2014potential therapeutic contribution of perivascular enzyme flow. Mol Ther. 2012;20:1489\u2013500.","journal-title":"Mol Ther."},{"key":"190_CR16","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","volume":"123","author":"V Haurigot","year":"2013","unstructured":"Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Investig. 2013;123:3254\u201371.","journal-title":"J Clin Investig."},{"key":"190_CR17","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.404709","volume":"196","author":"L Cork","year":"1977","unstructured":"Cork L, Munnell JF, Lorenz MD, Murphy JV, Baker HJ, Rattazzi MC. GM2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase deficiency. Science. 1977;196:1014\u20137.","journal-title":"Science."},{"key":"190_CR18","first-page":"723","volume":"90","author":"LC Cork","year":"1978","unstructured":"Cork LC, Munnell JF, Lorenz MD. The pathology of feline GM2 gangliosidosis. Am J Pathol. 1978;90:723\u201334.","journal-title":"Am J Pathol."},{"key":"190_CR19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.expneurol.2004.01.008","volume":"187","author":"DR Martin","year":"2004","unstructured":"Martin DR, Krum BK, Varadarajan G, Hathcock TL, Smith BF, Baker HJ. An inversion of 25 base pairs causes feline GM2 gangliosidosis variant 0. Exp Neurol. 2004;187:30\u201337.","journal-title":"Exp Neurol."},{"key":"190_CR20","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1073\/pnas.0603765103","volume":"103","author":"MB Cach\u00f3n-Gonz\u00e1lez","year":"2006","unstructured":"Cach\u00f3n-Gonz\u00e1lez MB, Wang SZ, Lynch A, Ziegler R, Cheng SH, Cox TM. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. PNAS. 2006;103:10373\u20138.","journal-title":"PNAS."},{"key":"190_CR21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/gt.2014.108","volume":"22","author":"VJ McCurdy","year":"2015","unstructured":"McCurdy VJ, Rockwell HE, Arthur JR, Bradbury AM, Johnson AK, Randle AN, et al. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease. Gene Ther. 2015;22:181\u20139.","journal-title":"Gene Ther."},{"key":"190_CR22","doi-asserted-by":"publisher","first-page":"175909141556990","DOI":"10.1177\/1759091415569908.","volume":"7","author":"HE Rockwell","year":"2015","unstructured":"Rockwell HE, McCurdy VJ, Eaton SC, Wilson DU, Johnson AK, Randle AN, et al. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system. ASN Neuro. 2015;7:1759091415569908. https:\/\/doi.org\/10.1177\/1759091415569908.","journal-title":"ASN Neuro."},{"key":"190_CR23","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1038\/mt.2013.86","volume":"21","author":"AM Bradbury","year":"2013","unstructured":"Bradbury AM, McCurdy VJ, Johnson AK, Gray-Edwards H, Brunson BL, Randle AN, et al. Intracranial AAV gene therapy extends the life span of GM2 gangliosidosis cats >four-fold with no clinical evidence of vector toxicity. Mol Ther. 2013;21:S226.","journal-title":"Mol Ther"},{"key":"190_CR24","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","volume":"128","author":"AE Bley","year":"2011","unstructured":"Bley AE, Giannikopoulos OA, Hayden D, Kubilus K, Tifft CJ, Eichler FS. Natural history of infantile GM2 gangliosidosis. Pediatrics. 2011;128:e1233\u201341.","journal-title":"Pediatrics."},{"key":"190_CR25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1469-8749.2011.04160.x","volume":"54","author":"NJ Smith","year":"2012","unstructured":"Smith NJ, Winstone A, Stellitano L, Cox TM, Verity CM. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed. Dev Med Child Neurol. 2012;54:176\u201382.","journal-title":"Dev Med Child Neurol."},{"key":"190_CR26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/hmg\/ddt459","volume":"23","author":"MB Cachon-Gonzalez","year":"2014","unstructured":"Cachon-Gonzalez MB, Wang SZ, Ziegler R, Cheng SH, Cox TM. Reversibility of neuropathology in Tay-Sachs-related diseases. Hum Mol Genet. 2014;23:730\u201348.","journal-title":"Hum Mol Genet."},{"key":"190_CR27","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/mt.2013.86","volume":"21","author":"AM Bradbury","year":"2013","unstructured":"Bradbury AM, Cochran JN, McCurdy VJ, Johnson AK, Brunson BL, Gray-Edwards H, et al. Therapeutic response in Feline Sandhoff disease despite immunity to intracranial gene therapy. Mol Ther. 2013;21:1306\u201315.","journal-title":"Mol Ther."},{"key":"190_CR28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.neuroscience.2005.11.057","volume":"138","author":"M Broekman","year":"2006","unstructured":"Broekman M, Comer L, Hyman B, Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience. 2006;138:501\u201310.","journal-title":"Neuroscience."},{"key":"190_CR29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2009.01.003","volume":"97","author":"AM Bradbury","year":"2009","unstructured":"Bradbury AM, Morrison NE, Hwang M, Cox NR, Baker HJ, Martin DR. Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency. Mol Genet Metab. 2009;97:53\u201357.","journal-title":"Mol Genet Metab."},{"key":"190_CR30","first-page":"434","volume":"19","author":"H Lacorazza","year":"1995","unstructured":"Lacorazza H, Jendoubi M. In situ assessment of beta-hexosaminidase activity. Biotechniques. 1995;19:434\u201340.","journal-title":"Biotechniques."},{"key":"190_CR31","doi-asserted-by":"crossref","first-page":"231ra48","DOI":"10.1126\/scitranslmed.3007733","volume":"6","author":"VJ McCurdy","year":"2014","unstructured":"McCurdy VJ, Johnson AK, Gray-Edwards HL, Randle AN, Brunson BL, Morrison NE. Sustained normalization of neurologic disease after intracranial gene therapy in a feline model. Sci Transl Med. 2014;6:231ra48.","journal-title":"Sci Transl Med."},{"key":"190_CR32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","volume":"15","author":"D Sondhi","year":"2006","unstructured":"Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM, et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh. 10 rhesus macaque-derived adeno-associated virus vector. Mol Ther. 2006;15:481\u201391.","journal-title":"Mol Ther."},{"key":"190_CR33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11745-008-3268-0","volume":"44","author":"RC Baek","year":"2009","unstructured":"Baek RC, Martin DR, Cox NR, Seyfried TN. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids. 2009;44:197\u2013205.","journal-title":"Lipids."},{"key":"190_CR34","doi-asserted-by":"crossref","first-page":"25859","DOI":"10.1074\/jbc.R200001200","volume":"277","author":"T Kolter","year":"2002","unstructured":"Kolter T, Proia RL, Sandhoff K. Combinatorial ganglioside biosynthesis. J Biol Chem. 2002;277:25859\u201362.","journal-title":"J Biol Chem."},{"key":"190_CR35","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1523\/JNEUROSCI.3558-04.2004","volume":"24","author":"A Cressant","year":"2004","unstructured":"Cressant A, Desmaris N, Verot L, Br\u00e9jot T, Froissart R, Vanier MT, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci. 2004;24:10229\u201339.","journal-title":"J Neurosci."},{"key":"190_CR36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5694\/mja12.11010","volume":"197","author":"RM Lew","year":"2012","unstructured":"Lew RM, Proos AL, Burnett L, Delatycki M, Bankier A, Fietz MJ. Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews. Med J Aust. 2012;197:652\u20134.","journal-title":"Med J Aust."},{"key":"190_CR37","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/mt.2013.138","volume":"21","author":"SS Ahmed","year":"2013","unstructured":"Ahmed SS, Li H, Cao C, Sikoglu EM, Denninger AR, Su Q, et al. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in canavan mice. Mol Ther. 2013;21:2136\u201347.","journal-title":"Mol Ther."},{"key":"190_CR38","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.mt.6300249","volume":"15","author":"MA Cabrera-Salazar","year":"2007","unstructured":"Cabrera-Salazar MA, Roskelley EM, Bu J, Hodges BL, Yew N, Dodge JC, et al. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther. 2007;15:1782\u20138.","journal-title":"Mol Ther."},{"key":"190_CR39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","volume":"19","author":"NM Ellinwood","year":"2011","unstructured":"Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther. 2011;19:251\u20139.","journal-title":"Mol Ther."},{"key":"190_CR40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/hum.2016.109","volume":"28","author":"D Golebiowski","year":"2017","unstructured":"Golebiowski D, van der Bom IMJ, Kwon C, Miller AD, Petrosky K, Bradbury AM, et al. Direct intracranial injection of AAVrh8 encoding monkey \u03b2-N-acetylhexosaminidase causes neurotoxicity in the primate brain. Hum Gene Ther. 2017;28:510\u201322.","journal-title":"Hum Gene Ther."},{"key":"190_CR41","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.gt.3300931","volume":"6","author":"S Elliger","year":"1999","unstructured":"Elliger S, Elliger C, Aguilar C, Raju N, Watson G. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther. 1999;6:1175\u20138.","journal-title":"Gene Ther."},{"key":"190_CR42","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/030098587901600602","volume":"16","author":"HJ Baker","year":"1979","unstructured":"Baker HJ, Reynolds GD, Walkley SU, Cox NR, Baker GH. The gangliosidoses: comparitive features and research applications. Vet Pathol. 1979;16:635\u201349.","journal-title":"Vet Pathol."},{"key":"190_CR43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.expneurol.2014.09.020","volume":"263","author":"AM Bradbury","year":"2015","unstructured":"Bradbury AM, Gray-Edwards H, Shirley JL, McCurdy VJ, Colaco AN, Randle AN, et al. Biomarkers for disease progression and AAV therapeutic efficacy in Feline Sandhoff disease. Exp Neurol. 2015;263:102\u201312.","journal-title":"Exp Neurol."},{"key":"190_CR44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymgme.2015.05.003","volume":"116","author":"HL Gray-Edwards","year":"2015","unstructured":"Gray-Edwards HL, Brunson BL, Holland M, Hespel AM, Bradbury AM, McCurdy VJ. Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy. Mol Genet Metab. 2015;116:80\u201387.","journal-title":"Mol Genet Metab."},{"key":"190_CR45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/hum.2017.151","volume":"29","author":"AM Bradbury","year":"2018","unstructured":"Bradbury AM, Bagel JH, Brisson BK, Marshall MS, Pesayco Salvador J, et al. AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). Hum Gene Ther. 2018;29:785\u2013801.","journal-title":"Hum Gene Ther."},{"key":"190_CR46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2015.189","volume":"24","author":"BL Gurda","year":"2016","unstructured":"Gurda BL, De Guilhem De Lataillade A, Bell P, Zhu Y, Yu H, Wang P, et al. Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol Ther. 2016;24:206\u201316.","journal-title":"Mol Ther"},{"key":"190_CR47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jgm.1372","volume":"11","author":"B Sun","year":"2009","unstructured":"Sun B, Zhang H, Bird A, Li S, Young SP, Koeberl DD. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high\u2010level vector\u2010mediated transgene expression. J Gene Med. 2009;11:913\u201320.","journal-title":"J Gene Med."},{"key":"190_CR48","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/brain\/awg089","volume":"126","author":"M Jeyakumar","year":"2003","unstructured":"Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d\u2019Azzo A. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003;126:974\u201387.","journal-title":"Brain."},{"key":"190_CR49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.neuroscience.2016.10.047","volume":"340","author":"AM Bradbury","year":"2016","unstructured":"Bradbury AM, Peterson TA, Gross AL, Wells SZ, McCurdy VJ, Wolfe KG. AAV mediated gene delivery attenuates neuroinflammation in Feline Sandhoff disease. Neuroscience. 2016;340:117\u201325.","journal-title":"Neuroscience."},{"key":"190_CR50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1750-3639.1998.tb00144.x","volume":"8","author":"SU Walkley","year":"1998","unstructured":"Walkley SU. Cellular pathology of lysosomal storage disorders. Brain Pathol. 1998;8:175\u201393.","journal-title":"Brain Pathol."},{"key":"190_CR51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0006-8993(87)80025-2","volume":"410","author":"S Walkley","year":"1987","unstructured":"Walkley S, Wurzelmann S, Siegel D. Ectopic axon hillock-associated neurite growth is maintained in metabolically reversed swainsonine-induced neuronal storage disease. Brain Res. 1987;410:89\u201396.","journal-title":"Brain Res."},{"key":"190_CR52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.20392","volume":"57","author":"CH Vite","year":"2005","unstructured":"Vite CH, McGowan JC, Niogi SN, Passini MA, Drobatz KJ, Haskins ME, et al. Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol. 2005;57:355\u201364.","journal-title":"Ann Neurol."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00190-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T13:08:29Z","timestamp":1630674509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":52,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["190"],"URL":"https:\/\/doi.org\/10.1038\/s41434-020-00190-1","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"19 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors are beneficiaries of a licensing agreement with Axovant Gene Therapies (New York City) based partly on this technology. MS-E and DRM are shareholders in Lysogene (Neuilly-sur-Seine, France).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}